期刊文献+

放疗与放化综合治疗晚期食管癌220例对比分析 被引量:3

Contrast Analysis of Radio-chemotherapy and Radiotherapy in the Treatment of Esophageal Carcinoma
暂未订购
导出
摘要 采用单纯放疗和放疗加化疗DFP方案(DDP、5-Fu、潘生丁)治疗晚期不宜手术的食管癌220例,单放组和综合组各110例,放疗剂量均为60~70Gy/6~7周,而化疗于放疗前两周完成。治疗结果:综合组完全缓解率83.6%(92/110)、单放组77.2%(85/110);1、2年生存率综合组为73.6%(81/110)、46.3%(51/110),单放组为47.2%(52/110)、20%(22/110)(P<0.01)。 From March 1990 to March 1992, our hospital gave treatment to 220 patients with esophageal carcinoma who were unable to have surgical operations. We devised two different schemes for the treatment, 110 cases having only radiotherapy and 110 cases having radiochemotherapyDFP scheme (DDP, 5-Fu, persantin). Both groups had the same radiotherapeutic dose of 60~70 Gy for 6~7 weeks. The Latter group had radiotherapy after two weedsl chemotherapy. The result after the treatment was as follows: disappearance of tumor:Group Ⅰ 77.2% (85/110),Group Ⅱ 83.6% (92/110). 1-,2- year survival rates:Group Ⅰ 47.2% (52/110),20% (22/110),Group Ⅱ73.6% (81/110),46.3% (51/110),P<0.01.
机构地区 河南省荣康医院
出处 《河南肿瘤学杂志》 1996年第3期196-197,共2页 Henan Journal of Oncology
关键词 食管癌 药物疗法 放射疗法 esophageal carcinoma, mere radiotherapy, radio-chemotherapy
  • 相关文献

参考文献5

二级参考文献3

  • 1陈志峰,刘少翔,侯浚.顺铂治疗食管癌现状[J].癌症,1990,9(3):255-258. 被引量:5
  • 2R. B. Schilcher,M. Wessels,N. Niederle,S. Seeber,C. G. Schmidt. Phase II evaluation of fractionated low and single high dose cisplatin in various tumors[J] 1984,Journal of Cancer Research and Clinical Oncology(1):57~60
  • 3杨光兴,郑秀立,周亭怡,唐桂棣.顺铂为主联合化疗治疗恶性肿瘤的疗效及毒副反应[J]癌症,1988(04).

共引文献21

同被引文献15

  • 1王瑞林,樊青霞,王志良,李苏宜.醛氢叶酸、5-氟脲嘧啶、顺铂疗法治疗食管癌的增效作用[J].中华肿瘤杂志,1995,17(5):362-364. 被引量:48
  • 2陈梅,郑崴,李云英.化疗加放疗及单用放疗治疗晚期食管癌82例疗效分析[J].肿瘤防治研究,1996,23(4):232-233. 被引量:6
  • 3乔学英 周道安.中晚期食管癌放射治疗配合卡铂的远期疗效[J].中华放射肿瘤学杂志,1997,6(2):118-119.
  • 4黄雪珍,吴晖,陈明强,陈枚,郭福榕.化疗与放疗综合治疗晚期食管癌64例[J].癌症,1997,16(3):215-216. 被引量:6
  • 5Sur M, Sur R, cooper K, et al.Morphologie alterations in esphageal spuamous cell carcinoma after preoperativehigh dose rate inte intraluminal brachytherapy[J].Caner,1996,77:2200-2205.
  • 6Shirasaka T,Shimamoto Y,Ohshimo H,et al.Development of a novel form of an oral 5-fluorouracil derivative(S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J].Anticancer Drugs,2006,7:548-57.
  • 7Diasio RB.Clinical implications of dihydropyrimidine ehydrogenase inhibition[J].Oncology(Williston Park),1999,13(Suppl):17-21.
  • 8E Van Cutsem,Hoff PM,Harper P,et al.Oral capecitabine vs intravenous 5-fluorouracil and leucovorin:integrated efficacy data and novel analyses from two large,randomized,phaseⅢ trials[J].British Journal of Cancer,2004,90:1190-1197.
  • 9Koji Harada,Shin-ichi Kawaquchi,Supriatno,et al.Combined effects of the oral fluoropyrimidine anticancer agent,S-1 and radiation on human oral cancer cells[J].Oral Oncology.2005,40(7):713-719.
  • 10Mingione V,oliveiva M,Prasad D,et al.Gamma knife surgery for melanoma metastases in the barin[J].J Neuorsurg,2002,96:544-551.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部